Results 141 to 150 of about 6,358 (191)

Potent 3-spiropiperidine growth hormone secretagogues

Bioorganic & Medicinal Chemistry Letters, 1998
Systematic SAR studies of the different regioisomers and homologues of the spiro(indane-1,4-piperidine) moiety in the growth hormone secretagogue L-162,752 are presented. Among them, spiro(3H-1-benzopyran-2,3-piperidine) was found to afford secretagogues with low nanomolar in vitro activity.
L, Yang, G, Morriello, K, Prendergast, K, Cheng, T, Jacks, W W, Chan, K D, Schleim, R G, Smith, A A, Patchett   +8 more
openaire   +2 more sources

Novel Orally Active Growth Hormone Secretagogues

Journal of Medicinal Chemistry, 1998
A novel class of growth hormone-releasing compounds with a molecular weight in the range from 500 to 650 has been discovered. The aim of this study was to obtain growth hormone secretagogues with oral bioavailability. By a rational approach we were able to reduce the size of the lead compound ipamorelin (4) and simultaneously to reduce hydrogen-bonding
T K, Hansen, M, Ankersen, B S, Hansen, K, Raun, K K, Nielsen, J, Lau, B, Peschke, B F, Lundt, H, Thøgersen, N L, Johansen, K, Madsen, P H, Andersen   +11 more
openaire   +2 more sources

Growth Hormone Secretagogues

Drugs, 1995
In recent years, several biosynthetic hexa- and heptapeptides, as well as nonpeptide bezolactam derivatives, have been found to be potent growth hormone (GH) secretagogues. They act synergistically with GH-releasing hormone (GHRH) but via different receptors, and are GHRH dependent.
openaire   +2 more sources

Growth hormone secretagogues astherapeutic agents

Growth Hormone & IGF Research, 1999
Growth hormone (GH) treatment increases growth velocity in children with GH deficiency (GHD), ~ and reverses most of the abnormalities observed in adults with GHD. 2 GH treatment has also been found to reduce body fat in obese men, 3 increase muscle mass in men over 60 years of age, 4 and partially reverse the catabolic effects of dietary energy ...
openaire   +2 more sources

Interactions of Growth Hormone Secretagogues and Growth Hormone-Releasing Hormone/Somatostatin

Endocrine, 2001
The class of novel synthetic compounds termed growth hormone secretagogues (GHSs) act in the hypothalamus through, as yet, unknown pathways. We performed physiologic and histochemical studies to further understand how the GHS system interacts with the well-established somatostatin (SRIF)/growth hormone-releasing hormone (GHRH) neuroendocrine system for
G S, Tannenbaum, C Y, Bowers
openaire   +2 more sources

Growth Hormone-Releasing Hormone and Growth Hormone Secretagogues in Normal Aging

Endocrine, 2003
Growth hormone (GH) secretion declines with aging, and parallels between normal aging and the signs and symptoms of adult GH deficiency have led to interest in the potential utility of replacing or stimulating GH to promote physical and psychological function and to prolong the capacity for independent living in older adults.
George R, Merriam, Robert S, Schwartz, Michael V, Vitiello   +2 more
openaire   +2 more sources

Growth hormone secretagogue receptor antagonists.

Expert opinion on therapeutic patents, 2012
The patent claims peptidic/nonpeptidic inhibitors of the ghrelin receptor, the growth hormone secretagogue receptor (GHSR) 1A. Among these compounds, it was disclosed that the addition in some compounds of a GlyMetAla tripeptide at the N-terminus of the ghrelin peptide agonists converts them into ghrelin receptor antagonists.
openaire   +3 more sources

New Active Series of Growth Hormone Secretagogues

Journal of Medicinal Chemistry, 2003
New growth hormone secretagogue (GHS) analogues were synthesized and evaluated for growth hormone releasing activity. This series derived from EP-51389 is based on a gem-diamino structure. Compounds that exhibited higher in vivo GH-releasing potency than hexarelin in rat (subcutaneous administration) were then tested per os in beagle dogs and for their
GUERLAVAIS V., BOEGLIN D., MOUSSEAUX D., OIRY C., HEITZ A., DEGHENGHI R., LOCATELLI V., TORSELLO A., GHE', Corrado, CATAPANO F., MUCCIOLI, Giampiero, GALLEYRAND JC, FEHRENTZ JA, MARTINEZ J.   +13 more
openaire   +3 more sources

GROWTH HORMONE SECRETAGOGUES: FOCUS ON THE GROWTH HORMONE-RELEASING PEPTIDES

Pharmacological Research, 1997
This review systematically analyses recent knowledge of the biology of the growth hormone-releasing peptides. Many years before native GHRH had been isolated and sequenced, the synthesis of an enkephalin analog, devoid of any opioid activity but capable of specifically releasing GH from in vitro pituitaries, prompted the design of a number of ...
V, Locatelli, A, Torsello
openaire   +2 more sources

Growth hormone secretagogues in children with altered growth

Acta Paediatrica, 1997
A diagnostic test was devised to evaluate pituitary growth hormone (GH) secretory potential. GH secretory dynamics were assessed in children with and without GH deficiency. The GH response was measured to GH‐releasing hormone (GHRH) and the GH‐releasing peptide GHRP‐2, administered sequentially.
B B, Bercu, R F, Walker
openaire   +2 more sources